Paper
0
Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
Authors
Marie Sébert,Sylvie Chevret
Sophie Dimicoli‐Salazar,Thomas Cluzeau,Odile Rauzy,Aspasia Bastard,Kamel Laribi,Gaëlle Fossard,Sylvain Thépot,Silke Gloaguen,Kristell Desseaux,Norbert Vey,Pierre Péterlin,Anne‐Laure Taksin,Caroline Lejeune,Sophie Park,Anne Banos,Aristoteles Giagounidis,Emmanuel Gyan,Mario Ojeda‐Uribe,Stefanie Groepper,Fatiha Chermat,Emmanuelle Clappier,Uwe Platzbecker,Pierre Fenaux
+23 authors
,Lionel AdèsJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave